February 6, 2011

2:30 pm – 4:30

Registration

Exhibitor &  Poster Setup

4:30 –  4:50

Welcome & Opening Remarks:

Overview of Drug Discovery for Neurodegenerative Diseases

Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation - read bio

4:50 – 5:20

PLENARY:

The Neurovascular Unit: Biology of Blood Brain Barrier in Neurodegenerative Diseases

Berislav Zlokovic, MD, PhD, University of Rochester - read bio

5:20 – 5:30

Q&A

5:30 – 5:35

Closing Remarks

Howard Fillit, MD, Alzheimer's Drug Discovery Foundation - read bio

5:35 – 7:00

Welcoming Reception

February 7, 2011

8:00 am – 8:30

Continental Breakfast

8:30 – 8:35

Welcome & Opening Remarks

Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

I. Basics of Medicinal Chemistry

Chair: D. Martin Watterson, PhD, Northwestern University

8:35 – 8:55

Overview: Medicinal Chemistry Rules of Thumb, Myths and Realities in CNS Drug Discovery

D. Martin Watterson, PhD, Northwestern University - read bio

8:55 – 9:05

Q&A

9:05 – 9:35

Designing Small Molecules with Increased Potential for CNS Penetration

Laura Chico, PhD, Robert W. Baird & Co.  

9:35 – 9:45

Q&A

9:45 – 10:15

Synthetic Chemistry Essentials for Biologists

Heather Behanna, PhD, JMP Securities LLC - read bio

10:15 – 10:25

Q&A

10:25 – 10:55

Structure Assisted Ligand Design

Vicki Nienaber, PhD, Zenobia Therapeutics, Inc. - read bio

10:55 – 11:05

Q&A

11:05 –  11:35

BREAK / VIEW POSTERS / EXHIBIT

II. Early Phases of Drug Discovery

Chair: Kurt R. Brunden, PhD, University of Pennsylvania

11:35 – 11:40

Session Overview – Kurt Brunden, PhD, University of Pennsylvania - read bio

11:40 am –  12:00 pm

Basics of High Throughput Screening (HTS)

James Inglese, PhD, National Institute of Health Chemical Genomics Center - read bio  

12:00 – 12:10

Q&A

12:10 –  12:30

After HTS: Solubility, Selectivity, Safety and Stability in Addition to Potency

Kurt Brunden, PhD, University of Pennsylvania - read bio

12:30 – 12:40

Q&A

12:40 –  1:00

Importance of Toxicology

John E. Sagartz, DVM, PhD, DACVP, Seventh Wave Laboratories - read bio

1:00 – 1:10

Q&A

1:10 – 2:25

LUNCH / VIEW POSTERS / EXHIBIT

III. Pre-Clinical Proof-of-Concept and Development

Chair: Edward Spack, PhD, Fast Forward, LLC

2:25 – 2:30

Session Overview – Edward Spack, PhD, Fast Forward, LLC - read bio

2:30 – 2:50

What Makes a Clinical Candidate?

William Potter, MD, PhD, Merck (Retired) - read bio

2:50 – 3:05

Q&A

3:05 – 3:20

Requirements for an IND

Edward Spack, PhD, Fast Forward, LLC - read bio

3:20 – 3:30

Q&A

3:30 – 4:00

BREAK / VIEW POSTERS / EXHIBIT

4:00 – 4:20

The Limitations and Value of Animal Models for Neurodegenerative Disease

Steve Perrin, PhD, ALS Therapy Development Institute - read bio

4:20 – 4:30

Q&A

4:30 – 4:50

Regulatory Requirements in Preparing for Clinical Trials

Eric Bastings, MD, Food and Drug Administration - read bio

4:50 - 5:00

Q&A

5:00 – 5:05

Closing Remarks

Howard Fillit, MD, Alzheimer's Drug Discovery Foundation

5:05 – 7:00

Networking and Poster Session

February 8, 2011

7:30 am – 8:00

Continental Breakfast

8:00 – 8:05

Welcome & Opening Remarks

Neil Buckholtz, PhD, National Institute on Aging - read bio

IV. Issues in Technology Transfer: Interactions and Intellectual Property

Chair: Kathleen Denis, PhD, Rockefeller University

8:05 – 8:10

Session Overview – Kathleen Denis, PhD, Rockefeller University - read bio

8:10 – 8:40

Working Effectively with Your TTO: Technology Evaluation Process and IP Protection

Kathleen Denis, PhD, Rockefeller University - read bio

8:40 – 8:50

Q&A

8:50 – 9:20

Creating Mutually Beneficial Relationships with Industry: Needs, Wants and Paperwork

Louis Berneman, EdD, CLP, Texelerate - read bio

9:20 – 9:30

Q&A

9:30 – 10:00

Should You Start a Biotechnology Company?

John S. Swartley, PhD, University of Pennsylvania - read bio

10:10 – 10:20

Q&A

10:20 – 10:40

BREAK / VIEW POSTERS / EXHIBIT

V. Beyond Small Molecules: Natural Products, Biologics and Repurposing

Chair: Diana Shineman, PhD, Alzheimer’s Drug Discovery Foundation - read bio

10:40 – 10:45

Session Overview –  Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation

10:45 – 11:05

Natural Products as Drug Starting Points

Frank Koehn, PhD, Pfizer Inc. - read bio

11:05 – 11:15

Q&A

11:15 – 11:35

Unique Challenges for Biologics

Joao Siffert, PhD, Ceregene, Inc. - read bio

11:35 – 11:45

Q&A

11:45 am – 12:05 pm

The Road to Repurposing a Drug: Isradipine

D. James Surmeier, PhD, Northwestern University - read bio

12:05 – 12:15

Q&A

12:15 – 1:15

LUNCH / VIEW POSTERS / EXHIBIT

VI. Case Studies

Chair: Brian Fiske, PhD, Michael J. Fox Foundation for Parkinson’s Research

1:15 – 1:20

Session Overview –  Brian Fiske, PhD, Michael J. Fox Foundation for Parkinson's Research - read bio

1:20 – 1:40

Neurotrophic Factor Mimetics: Target Validation to Lead Optimization

Frank Longo, MD, PhD, Stanford University - read bio

1:40 – 1:50

Q&A

1:50 –  2:10

Development of Tysabri for Multiple Sclerosis

Ted Yednock, PhD, Elan Pharmaceuticals, Inc.

2:10 –  2:20

Q&A

2:20 – 2:40

Novel Ways to Reduce Protein Aggregation

Alan Snow, PhD, ProteoTech, Inc.

2:40 – 3:00

Q&A

3:00  – 3:30 pm

BREAK / VIEW POSTERS / EXHIBIT

VII. Resources and Services For Advancing Drug Discovery

Chair: Suzana Petanceska, PhD, National Institute on Aging

3:30 – 3:35

Session Overview – Suzana Petanceska, PhD, National Institute on Aging - read bio

3:35 – 3:55

Academic Models of Drug Discovery Services & Utilizing CROs

Marcie Glicksman, PhD, Harvard NeuroDiscovery Center - read bio

3:55 – 4:05

Q&A

4:05 – 4:25

Resources at the National Institute of Health

Rebecca Farkas, PhD, National Institute on Neurological Disorders and Stroke - read bio

Neil Buckholtz, PhD, National Institute on Aging - read bio 

4:25 – 4:45

Q&A

4:45 – 4:55

Closing Remarks

Howard Fillit, MD, Alzheimer's Drug Discovery Foundation - read bio